The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! The stock decreased 5.09% or $0.88 during the last trading session, hitting $16.5. About 696,971 shares traded hands or 63.14% up from the average. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 63.81% since April 27, 2016 and is uptrending. It has outperformed by 58.58% the S&P500.
The move comes after 8 months negative chart setup for the $506.17M company. It was reported on Nov, 30 by Barchart.com. We have $15.02 PT which if reached, will make NASDAQ:FLXN worth $45.56M less.
Analysts await Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings on March, 9. They expect $-0.75 EPS, down 19.05% or $0.12 from last year’s $-0.63 per share. After $-0.65 actual EPS reported by Flexion Therapeutics Inc for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.
Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage
Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Lake Street initiated the stock with “Buy” rating in Thursday, July 21 report. Cantor Fitzgerald initiated the stock with “Buy” rating in Wednesday, November 4 report. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, June 29. Wells Fargo reinitiated the stock with “Outperform” rating in Tuesday, May 3 report. Needham maintained the shares of FLXN in a report on Wednesday, September 9 with “Buy” rating.
According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.54 in 2016 Q2. Its down 1.31, from 2.85 in 2016Q1. The ratio is negative, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
Moreover, Tower Limited Liability (Trc) has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 441 shares. Blackrock Advisors Lc holds 0% or 26,726 shares in its portfolio. Allianz Asset Management Ag holds 0% or 257,092 shares in its portfolio. Oxford Asset has 0.13% invested in the company for 209,593 shares. Schwab Charles Investment Management accumulated 28,943 shares or 0% of the stock. Credit Suisse Ag has 0% invested in the company for 17,670 shares. Bridgeway Capital Inc, a Texas-based fund reported 44,000 shares. Moreover, Thompson Davis And Company has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 125 shares. Deutsche Financial Bank Ag owns 14,461 shares or 0% of their US portfolio. Proshare Advsrs Ltd Liability reported 18,320 shares or 0% of all its holdings. Amici Limited Company, a New York-based fund reported 20,000 shares. Geode Cap Management Lc holds 145,396 shares or 0% of its portfolio. Alps Advisors Inc owns 30,301 shares or 0% of their US portfolio. The Kentucky-based Teachers Retirement Systems Of The State Of Kentucky has invested 0.01% in Flexion Therapeutics Inc (NASDAQ:FLXN). The North Carolina-based State Bank Of America Corporation De has invested 0% in Flexion Therapeutics Inc (NASDAQ:FLXN).
Insider Transactions: Since June 8, 2016, the stock had 8 insider purchases, and 0 insider sales for $30.70 million net activity. $599,994 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) was bought by COLELLA SAMUEL D on Monday, November 21. $10.00M worth of shares were bought by Versant Ventures III – LLC on Wednesday, June 8. Clayman Michael D. also bought $29,900 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) shares. Shares for $13,387 were bought by MERRIFIELD C ANN on Tuesday, June 14. LUBASH BARBARA N had bought 714,285 shares worth $10.00M on Wednesday, June 8.
More news for Flexion Therapeutics Inc (NASDAQ:FLXN) were recently published by: Fool.com, which released: “Why Shares of Flexion Therapeutics, Inc., Lantheus Holdings Inc, and PDL …” on November 16, 2016. Fool.com‘s article titled: “Can Flexion Therapeutics Add Some Muscle to Your Portfolio?” and published on November 17, 2016 is yet another important article.
FLXN Company Profile
Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.